Session information

Symposium

[SY18] Symposium 18　PARP inhibitor for Ovarian Cancer Treatment
【SI】【E】

Fri. Feb 18, 2022 3:05 PM - 4:35 PM Room 7 (Room E, 1F, Kyoto International Conference Center)

Chair：Keiichi Fujiwara（Department of Gynecologic Oncology, Saitama Medical University），Mansoor Raza Mirza（Department of Oncology, The Nordic Society of Gynecological Oncology and Rigshospitalet-Copenhagen University Hospital）

+Add all to schedule

[SY18-1] Niraparib for ovarian cancer

^○Mansoor Raza Mirza (The Nordic Society of Gynecological Oncology and Rigshospitalet-Copenhagen University Hospital)

[SY18-2] PARP-inhibitors in epithelial ovarian cancer: actual positioning and future expectations

^○Isabelle Ray-Coquard (Department of Medical Oncology, University Claude Bernard Lyon1-
Centre Léon Bérard)

[SY18-3] Mechanisms of acquired resistance to platinum compounds and PARP inhibitors in BRCA1/2-mutated cancer cells

^○Toshiyasu Taniguchi (Department of Molecular Life Science, Tokai University School of Medicine)

[SY18-4] The reason why platinum sensitivity is used for a clinical biomarker of PARP inhibitor sensitivity may be explained by the Schlafen 11 (SLFN11)

^○Murai Junko (Institute for Advanced Biosciences, Keio University)

▲